Pfizer Inc. (PFE)
NYSE: PFE · Real-Time Price · USD
25.25
+0.58 (2.35%)
At close: Jul 28, 2026, 4:00 PM EDT
25.26
+0.01 (0.04%)
After-hours: Jul 28, 2026, 4:14 PM EDT

Pfizer Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
7,5237,7878,0512,17331,40122,459
Depreciation & Amortization
6,5876,5927,0136,2905,0645,191
Stock-Based Compensation
9017998775258721,182
Other Adjustments
2,1431,881-1321,886-2,431-8,713
Change in Receivables
--263-109347261-3,811
Changes in Inventories
-561-854-1,169-591-1,125
Changes in Accounts Payable
--469-1,023-3001,1911,242
Changes in Accrued Expenses
--3,667-3,115595-1,44918,721
Changes in Income Taxes Payable
--2,805-1,345-982-545-1,166
Changes in Other Operating Activities
-6,7571,2893,380-663-4,506-1,057
Operating Cash Flow
11,98411,70412,7448,70029,26732,580
Operating Cash Flow Growth
-14.33%-8.16%46.48%-70.27%-10.17%126.20%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-2,501-2,629-2,909-3,907-3,236-2,711
Purchases of Investments
-14,366-14,650-10,313-31,178-38,297-39,525
Proceeds from Sale of Investments
19,68119,0545,69841,24345,46228,096
Cash Acquisitions
--6,927--43,430-22,997-
Proceeds from Business Divestments
-6,3117,040---
Other Investing Activities
272-2,5103,1384,9953,285-8,393
Investing Cash Flow
-3,840-1,3512,652-32,278-15,783-22,546

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-537-7966,3177,6863,669-96
Short-Term Debt Repaid
-151-2,199-11,226-3-3,887-
Net Short-Term Debt Issued (Repaid)
-688-2,995-4,9097,683-218-96
Long-Term Debt Issued
-2,921-2,25028,262-3,298-1,007
Net Long-Term Debt Issued (Repaid)
-2,921-2,25028,262-3,298-1,007
Repurchase of Common Stock
-----2,000-
Net Common Stock Issued (Repurchased)
-----2,000-
Common Dividends Paid
-9,779-9,771-9,512-9,247-8,983-8,729
Other Financing Activities
-386-458-469-631-33516
Financing Cash Flow
-7,933-10,304-17,14026,066-14,834-9,816

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
6741-66-40-165-59
Net Cash Flow
27991-1,8102,448-1,515159

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
9,4839,0759,8354,79326,03129,869
Free Cash Flow Growth
-15.48%-7.73%105.19%-81.59%-12.85%145.29%
FCF Margin
14.98%14.50%15.46%8.05%25.73%36.74%
Free Cash Flow Per Share
1.661.591.730.844.545.23
Levered Free Cash Flow
4,1316,5692,01937,92823,78439,971
Unlevered Free Cash Flow
4,8506,6589,1982,03527,32741,554
SEC Filings: 10-K · 10-Q